Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

Black, Dennis M.; Delmas, Pierre D.; Eastell, Richard; Reid, Ian R.; Boonen, Steven; Cauley, Jane A.; Cosman, Felicia; Lakatos, Péter; Leung, Ping Chung; Man, Zulema; Mautalén, C.; Mesenbrink, Peter; Hu, Huilin; Caminis, John; Tong, Karen; Rosario-Jansen, Theresa; Krasnow, Joel; Hue, Trisha F.; Sellmeyer, Deborah E.; Eriksen, Erik Fink; Cummings, Steven R.

doi:10.1056/nejmoa067312

Cited by 2,565 publications

(1,857 citation statements)

References 33 publications

Supporting

Mentioning

1,635

Contrasting

Unclassified

106

Order By: Relevance

“…The efficacy of yearly infusions of zoledronate 5 mg over three years was assessed in postmenopausal women in a placebo controlled fashion (HORIZON study [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly]) 98. Zoledronate was found to reduce the incidence of vertebral fractures by 70% and that of hip fractures by 40%.…”

Section: Pharmacotherapy Of Osteoporosismentioning

confidence: 99%

Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective

Raef

Al-Bugami

Balharith

et al. 2011

Annals of Saudi Medicine

View full text Add to dashboard Cite

Postmenopausal osteoporosis and osteoporosis in elderly men are major health problems, with a significant medical and economic burden. Although osteopenia and osteoporosis are more common locally than in the West, fracture rates are generally less than in Western countries. Vitamin D deficiency is common in the region and contributes adversely to bone health. Vitamin D deficiency should be suspected and treated in all subjects with ostopenia or osteoporosis. The use of risk factors to determine fracture risk has been adopted by the World Health Organization and many international societies. Absolute fracture risk methodology improves the use of resources by targeting subjects at higher risk of fractures for screening and management. The King Faisal Specialist Hospital Osteoporosis Working Group recommends screening for women 65 years and older and for men 70 years and older. Younger subjects with clinical risk factors and persons with clinical evidence of osteoporosis or diseases leading to osteoporosis should also be screened. These guidelines provide recommendations for treatment for postmenopausal women and men older than 50 years presenting with osteoporotic fractures for persons having osteoporosis—after excluding secondary causes—or for persons having low bone mass and a high risk for fracture. The Working Group has suggested an algorithm to use at King Faisal Specialist Hospital that is based on the availability, cost, and level of evidence of various therapeutic modalities. Adequate calcium and vitamin D supplement are recommended for all. Weekly alendronate (in the absence of contraindications) is recommended as first-line therapy. Alternatives to alendronate are raloxifene or strontium ranelate. Second-line therapies are zoledronic acid intravenously once yearly, when oral therapy is not feasible or complicated by side effects, or teriparatide in established osteoporosis with fractures.

show abstract

Section: Pharmacotherapy Of Osteoporosismentioning

confidence: 99%

Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective

Raef

Al-Bugami

Balharith

et al. 2011

Annals of Saudi Medicine

View full text Add to dashboard Cite

show abstract

“…Bisphosphonates are today's worldwide leading medication [7][8][9][10][11][12][13][14][15][16] and are recommended as first-line treatments for osteoporosis [1,2,17,18]. Two chemically distinct groups of bisphosphonates exist: Simple non-nitrogen-containing bisphosphonates (Non-N-BP's, e.g., Etidronate) and nitrogen-containing bisphosphonates (N-BP´s) e.g., Ibandronate, Alendronate, Zoledronate and Risedronate).…”

Section: Bisphosphonates Are the Most Common Therapy For Osteoporosismentioning

confidence: 99%

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Ringe

Möller

2009

Rheumatol Int

View full text Add to dashboard Cite

“…Nestes casos deve-se tomar cuidado com o uso oral do medicamento pelos efeitos irritativos sobre o aparelho digestivo. Entretanto, mesmo em relação a este aspecto, há tendência de surgirem bisfosfonatos de efeito mais prolongado, quando aplicados por via endovenosa, como o ácido zoledrô-nico que em uma única dose anual pode ser um tratamento eficaz para osteoporose pós-menopausa (42)(43) .…”

Section: Discussionunclassified

O alendronato de sódio na prevenção da osteopenia secundária à imobilização gessada, em ratas: avaliação histomorfométrica

et al. 2008

View full text Add to dashboard Cite

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

Abstract: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)

Cited by 2,565 publications

References 33 publications

Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective

Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

O alendronato de sódio na prevenção da osteopenia secundária à imobilização gessada, em ratas: avaliação histomorfométrica

Contact Info

Product

Resources

About